Oncopeptides AB (publ)

BATS-CHIXE:ONCOS Stock Report

Market Cap: SEK 942.1m

Oncopeptides Future Growth

Future criteria checks 2/6

Oncopeptides is forecast to grow earnings and revenue by 44.1% and 87.4% per annum respectively while EPS is expected to grow by 66.6% per annum.

Key information

44.1%

Earnings growth rate

66.6%

EPS growth rate

Biotechs earnings growth37.8%
Revenue growth rate87.4%
Future return on equityn/a
Analyst coverage

Low

Last updated08 May 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:ONCOS - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025338-43-43-431
12/31/2024177-198-198-1981
12/31/202326-335-362-3622
3/31/20239-310-346-343N/A
12/31/20228-338-423-421N/A
9/30/2022-14-641-790-789N/A
6/30/202241-1,330-1,055-1,055N/A
3/31/202299-1,294-1,296-1,296N/A
12/31/2021118-1,430-1,517-1,516N/A
9/30/2021140-1,549-1,444-1,427N/A
6/30/202186-1,155-1,449-1,431N/A
3/31/202119-1,532-1,388-1,370N/A
12/31/2020N/A-1,595-1,314-1,297N/A
9/30/2020N/A-1,327-1,159-1,156N/A
6/30/2020N/A-1,133-1,026-1,023N/A
3/31/2020N/A-904-863-861N/A
12/31/2019N/A-741-693-691N/A
9/30/2019N/A-608-583-582N/A
6/30/2019N/A-512-469-469N/A
3/31/2019N/A-485-436-436N/A
12/31/2018N/A-411-334-334N/A
9/30/2018N/A-368-272-271N/A
6/30/2018N/A-325-263-262N/A
3/31/2018N/A-248-246-244N/A
12/31/2017N/A-250-273-271N/A
9/30/2017N/A-243-271-270N/A
6/30/2017N/A-216-214-211N/A
3/31/2017N/A-172-160-159N/A
12/31/2016N/A-125N/A-104N/A
12/31/2015N/A-62N/A-53N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ONCOS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ONCOS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ONCOS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ONCOS's revenue (87.4% per year) is forecast to grow faster than the UK market (4% per year).

High Growth Revenue: ONCOS's revenue (87.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ONCOS's Return on Equity is forecast to be high in 3 years time


Discover growth companies